News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Subscribe To Our Newsletter & Stay Updated
